On November 19, 2025, Aptose Biosciences Inc. (“Aptose”) announced that it entered into a definitive arrangement agreement with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi, pursuant to which Hanmi will acquire all of the issued and outstanding common shares of Aptose not already owned or controlled by Hanmi or its affiliates for C$2.41 per share in cash, representing an aggregate transaction value of approximately C$4.2 million, in addition to prior debt facilities provided by Hanmi totaling more than US$30 million. The transaction will be completed by way of a plan of arrangement under the Business Corporations Act (Alberta), following Aptose’s continuance from the Canada Business Corporations Act to Alberta to facilitate the arrangement under provincial law.
Hanmi currently owns approximately 19.93% of Aptose’s outstanding common shares and has provided significant financial support through debt facilities totaling more than US$30 million. This acquisition represents Hanmi’s first direct entry into the North American market and is expected to support the continued development of Aptose’s lead compound, tuspetinib, in the TUSCANY Phase 1/2 clinical study for acute myeloid leukemia.
Aptose is a clinical-stage biotechnology company headquartered in Toronto, Ontario, with operations in San Diego, California, focused on developing precision medicines for oncology.
Hanmi Pharmaceutical, headquartered in Seoul, South Korea, is a global biopharmaceutical company specializing in oncology, diabetes, obesity, and metabolic diseases. HS North America Ltd., Hanmi’s subsidiary, is based in New Jersey.
McCarthy Tétrault LLP advised Aptose Biosciences with a team led by Charles-Antoine Souliere that included Farhiyah Shariff, James Lin, Sabih Ottawa, Michel Ranger, Julien Leblanc, Audrey Bouffard-Nesbitt, Rhea Evans, Jamey Gage, Lyndsey Delamont, Robert Hansen, Charles Morin, Rebecca Wieschkowski, Tasia Ntwari, Elle Anderson, Rebecca Thomas, and Annie Poirier-Simard.